Further diabetes drug hope in Korean Scottish alliance

The government of South Korea have made the decision to fun collaborative research in drug development between Scottish Biomedical and Chong Kun Dang. The Korean Health Industry Development Institute will bring together the Glasgow company and their Korean counterparts under the umbrella of the International Collaborative Research Programme for Drug Development (ICRPDD).
Of the seven major international projects put forward to the Health Industry Development Institute last year, only two were successful in winning funding. The larger of the two is a multi-year agreement to study new drug development in metabolic ailments, and especially in diabetes. The research will be based on a new mechanism devised by Scottish Biomedical and South Korean pharmaceutical company Chong Kun Dang.
The Business Development Director of Scottish Biomedical, Simon Bury, stated that “We are delighted to be working with Chong Kun Dang on this important project and to have won the funding in the face of truly global competitio,” he went on to say, “This is a great endorsement of the strength of the Scottish life sciences industry and to the work undertaken by SDI in establishing these relationships and opportunities.”
Hopefully the partnership will bring to light further developments in the fight against diabetes.